Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP)
February 24, 2023 07:23 AM ESTUpdated 09:32 AM
R&D

No­var­tis re­treat from NASH takes down $80M al­liance with Pli­ant Ther­a­peu­tics

Amber Tong

Back in 2019, No­var­tis com­mit­ted $80 mil­lion to col­lab­o­rate with Pli­ant Ther­a­peu­tics on a pre­clin­i­cal can­di­date to treat liv­er fi­bro­sis as­so­ci­at­ed with non­al­co­holic steato­hep­ati­tis, or …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times